Chakraborty S, et al. - A randomized, placebo-controlled study was performed from March 2013 through March 2017 to determine the impacts of alfuzosin, an alpha1-adrenergic receptor antagonist, on anal pressures alone in healthy women and furthermore on bowel symptoms in women with defecatory disorders (DD). Compared with placebo, alfuzosin reduced anal pressure at rest and during a simulated evacuation in healthy and constipated women. It was noted that alfuzosin did not improve bowel symptoms in constipated women and this could be because the drug does not improve stool form or dyssynergia, which also contribute to DD.